ALKS

Today, 10:47 AMAlkermes posts Q3 2026 net income $16.3M ($0.09/share) on revenue $480.1M (+22% YoY), beating earnings and revenue estimates

Peers: NBIX INDV JAZZ TEVA TAK SUPN AXSM HRMY ACAD JNJ

| Held by: IJR VTI IWM VB XBI FBT VBK VXF SPSM IJT

Scroll to Statements

Index	RUT
Market Cap	7.88B
Enterprise Value	8.80B
Income	66.12M
Sales	1.67B
Book/sh	10.79
Cash/sh	3.91
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	2050
IPO	Jul 16, 1991

P/E	122.06
Forward P/E	86.29
PEG	-
P/S	4.73
P/B	4.35
P/C	12.01
P/FCF	35.57
EV/EBITDA	42.86
EV/Sales	5.28
Quick Ratio	1.85
Current Ratio	2.30
Debt/Eq	0.87
LT Debt/Eq	0.85
Option/Short	Yes / Yes

EPS (ttm)	0.39
EPS next Y	0.54
EPS next Q	-0.09
EPS this Y	-137.88%
EPS next Y	200.56%
EPS next 5Y	-11.16%
EPS past 3/5Y	- -
Sales past 3/5Y	9.90% 7.28%
EPS Y/Y TTM	-81.14%
Sales Y/Y TTM	10.79%
EPS Q/Q	-99.44%
Sales Q/Q	26.97%
Earnings	Nov 03 BMO
EPS/Sales Surpr.	210.29% 3.59%

Insider Own	2.98%
Insider Trans	-2.31%
Inst Own	105.39%
Inst Trans	-0.53%
ROA	1.99%
ROE	3.85%
ROIC	1.98%
Gross Margin	82.13%
Oper. Margin	8.62%
Profit Margin	3.97%
SMA20	9.60%
SMA50	6.92%
SMA200	15.69%
Trades

Shs Outstand	167.54M
Shs Float	162.76M
Short Float	11.70%
Short Ratio	10.36
Short Interest	19.05M
52W High	55.67 -15.59%
52W Low	27.00 74.05%
Volatility	3.20% 3.39%
ATR (14)	1.54
RSI (14)	66.45
Beta	0.29
Rel Volume	1.12
Avg Volume	1.84M
Volume	1,092,696

Perf Week	6.03%
Perf Month	9.90%
Perf Quarter	-5.27%
Perf Half Y	29.64%
Perf YTD	67.95%
Perf Year	55.76%
Perf 3Y	103.92%
Perf 5Y	65.10%
Perf 10Y	-1.13%
Recom	1.63
Target Price	56.37
Prev Close	44.89
Price	46.99
Change %	4.69%

Consensus

Buy

Avg. Price Target

$56.37

Implied Upside

+20.0%

Analysts14incl. previous ratings

Rating Distribution12 Buy · 1 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 16, 2026	Initiated	TTruist	Buy	$55	+17.0%
Jul 13, 2026	Resumed	JJP Morgan	Neutral	$60	+27.7%
Jun 29, 2026	Downgrade	BBofA Securities	Neutral → Underperform	$38	-19.1%
Feb 24, 2026	Initiated	WWolfe Research	Outperform	$45	-4.2%
Nov 11, 2025	Initiated	TTruist	Buy	$50	+6.4%
Sep 26, 2025	Upgrade	RRBC Capital Mkts	Sector Perform → Outperform	$44	-6.4%
Sep 03, 2025	Initiated	WWells Fargo	Overweight	$44	-6.4%
Jul 15, 2025	Initiated	GGoldman	Buy	$43	-8.5%
Jun 17, 2025	Upgrade	UUBS	Neutral → Buy	$42	-10.6%
May 28, 2025	Initiated	NNeedham	Buy	$45	-4.2%
Mar 13, 2025	Initiated	RRBC Capital Mkts	Sector Perform	$40	-14.9%
Mar 04, 2025	Upgrade	UUBS	Sell → Neutral	$21 → $38	-19.1%
Feb 11, 2025	Initiated	DDeutsche Bank	Buy	$40	-14.9%
Nov 05, 2024	Upgrade	SStifel	Hold → Buy	$25 → $36	-23.4%
Jun 17, 2024	Initiated	TTD Cowen	Buy	$34	-27.6%
Mar 19, 2024	Initiated	RRobert W. Baird	Outperform	$37	-21.3%
Feb 20, 2024	Downgrade	UUBS	Neutral → Sell	$25	-46.8%
Nov 20, 2023	Resumed	JJP Morgan	Neutral	$33	-29.8%
Oct 24, 2023	Upgrade	EEvercore ISI	In-line → Outperform
Oct 17, 2023	Initiated	UUBS	Neutral	$31	-34.0%

Today 10:28AM	Alkermes Beats Its Own Guidance, But Lybalvi Pricing Dilution And Takeda's Orexin Launch Cloud A Stronger Quarter (Earnings Whispers)
07:12AM	Alkermes: Q3 Earnings Snapshot (Associated Press)
06:05AM	Alkermes plc Reports Third Quarter 2026 Financial Results (Business Wire)
Oct-30-26 07:00AM	Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD) (Business Wire)
Oct-26-26 03:20PM	Alkermes Faces A Planned Profit Dip As R&D Ramp Tests Orexin Optimism (Earnings Whispers)
04:00PM	Loading…
Oct-20-26 04:00PM	Alkermes to Report Third Quarter Financial Results on November 3, 2026 (Business Wire)
Oct-16-26 09:38AM	Workday downgraded, Fox Corp. upgraded: Wall Street's top analyst calls (The Fly)
Oct-13-26 07:00AM	Alkermes to Present New Data on Alixorexton and LUMRYZ (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research (Business Wire)
Sep-22-26 10:17AM	An orexin drugs proof-of-concept in ADHD; Cues unwarranted share slide (BioPharma Dive)
Sep-21-26 04:20PM	How Alkermes Used Its Narcolepsy Playbook In ADHD - And Seemingly Won (Investor's Business Daily)
08:41AM	Alkermes Shares Rise 6.5% After Positive Phase 1b Results for ADHD Drug ALKS 7290 (InvestorsHub)
Sep-16-26 07:00AM	Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors (Business Wire)
Sep-10-26 07:00AM	Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards Program (Business Wire)
Aug-24-26 06:30PM	The Lancet Neurology Publishes Data From Alkermes Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1 (Business Wire)
Aug-06-26 02:30PM	The Race to Come Up With the Next Big Sleep Drug (The Wall Street Journal)
03:01PM	Loading…
Jul-28-26 03:01PM	Alkermes PLC (ALKS) Q2 2026 Earnings Call Highlights: Strong Sales Growth Amidst Competitive ... (GuruFocus.com)
07:00AM	Alkermes plc Reports Second Quarter 2026 Financial Results (Business Wire)
Jul-14-26 04:00PM	Alkermes to Report Second Quarter Financial Results on July 28, 2026 (Business Wire)
Jul-13-26 09:41AM	American Express, Biogen upgraded: Wall Street's top analyst calls (The Fly)
07:00AM	Alkermes' Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis (Business Wire)
Jun-29-26 12:01PM	BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns (Investing.com)
09:44AM	Adobe downgraded, Roblox upgraded: Wall Street's top analyst calls (The Fly)
Jun-26-26 05:46AM	Alkermes incoming CEO has a plan to outplay Lilly and Takeda (BioPharma Dive)
Jun-17-26 04:15PM	Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026 (Business Wire)
Jun-15-26 07:00AM	Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe (Business Wire)
Jun-12-26 05:31AM	Rapport fully prepared to launch seizure drug solo, CEO says (BioPharma Dive)
Jun-04-26 07:00AM	Alkermes to Present New Data on Alixorexton and LUMRYZ (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research (Business Wire)
Jun-03-26 04:05PM	Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference (Business Wire)
May-26-26 07:00AM	Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting (Business Wire)
May-21-26 07:00AM	Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences (Business Wire)
07:00AM	Loading…
May-12-26 07:00AM	Alkermes Announces Positive Topline Results From REVITALYZ Phase 3 Study Evaluating LUMRYZ (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia (Business Wire) +7.95%
May-05-26 07:06AM	Alkermes: Q1 Earnings Snapshot (Associated Press) +6.09%
07:00AM	Alkermes plc Reports First Quarter 2026 Financial Results (Business Wire)
Apr-21-26 04:05PM	Alkermes to Report First Quarter Financial Results on May 5, 2026 (Business Wire)
Apr-16-26 07:00AM	Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting (Business Wire)
Apr-14-26 07:00AM	Findings From Long-Term Analysis of the Effects of LYBALVI (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry (Business Wire)
Apr-13-26 07:06AM	Preparation is key to understanding global trade compliance for trials (Clinical Trials Arena)
Apr-01-26 07:00AM	Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2 (Business Wire)
Mar-12-26 07:00AM	Alkermes Announces Inaugural Alkermes Pathways APN Research Awards Program (Business Wire)
Mar-11-26 05:11AM	New Strong Sell Stocks for March 11th (Zacks)
Mar-10-26 04:00PM	Alkermes to Present at the Stifel 2026 Virtual CNS Forum (Business Wire)
Mar-06-26 03:00AM	Biopharmas recent string of CEO splits (Pharma Voice)
Mar-02-26 10:02PM	Alkermes Pivots Deeper Into Sleep Medicine After Avadel Deal, Details Orexin Phase 3 at TD Cowen (MarketBeat)
Feb-26-26 11:40AM	Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change (Zacks)
Feb-25-26 02:03PM	Alkermes PLC (ALKS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) -7.04%
12:30PM	Alkermes (ALKS) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
12:15PM	Alkermes (ALKS) Q4 Earnings and Revenues Top Estimates (Zacks)
11:02AM	Alkermes Q4 Earnings Call Highlights (MarketBeat)
07:43AM	Alkermes: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026 (Business Wire)
06:55AM	Alkermes plc Announces CEO Succession Plan (Business Wire)
06:54AM	Alkermes Richard Pops to step down after three-decade run as CEO (BioPharma Dive)
Feb-24-26 04:00PM	Alkermes to Present at the TD Cowen 46th Annual Health Care Conference (Business Wire)
09:15AM	Wall Street's Insights Into Key Metrics Ahead of Alkermes (ALKS) Q4 Earnings (Zacks)
08:00AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Blackstone, Blue Owl Capital, Booking Holdings, Cheniere Energy, Comcast, Dominos Pizza, KeyCorp, Qualcomm, and More (24/7 Wall St.)
Feb-19-26 11:59AM	BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth (Zacks)
07:34AM	ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up (Zacks)
Feb-18-26 11:31AM	FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma (Zacks)
11:24AM	Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark (Zacks)
09:41AM	EU Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients (Zacks)
09:40AM	Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:32AM	Cytokinetics Wins EU Approval for Cardiovascular Drug Myqorzo (Zacks)
Feb-17-26 12:10PM	Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Feb-13-26 01:11PM	Waters Q4 Earnings Surpass Estimates, Revenues Increase Y/Y (Zacks)
12:55PM	SNY Stock Falls After Board Suddenly Makes Leadership Change (Zacks)
11:53AM	VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales (Zacks)
10:33AM	Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss (Zacks)
10:23AM	Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
10:20AM	NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia (Zacks)
10:19AM	ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down (Zacks)
10:04AM	CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates (Zacks)
Feb-12-26 10:38AM	MDGL Strengthens MASH Franchise With New Genetic Approaches (Zacks)
10:30AM	Zoetis Stock Gains After Q4 Earnings & Revenues Beat Estimates (Zacks)
07:30AM	Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market (Business Wire)
Feb-11-26 04:00PM	Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026 (Business Wire)
12:57PM	Pharma companies left out of Trump's drug-pricing deals look for way in (Reuters)
10:45AM	MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLA (Zacks)
Feb-10-26 10:43AM	SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status (Zacks)
10:38AM	INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales (Zacks)
Feb-09-26 11:42AM	IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus (Zacks)
Feb-06-26 01:58PM	Mettler-Toledo Q4 Earnings Top Estimates, Sales Rise Y/Y (Zacks)
11:45AM	GSK Gets EU Approval for Expanded Use of Nucala in COPD (Zacks)
11:31AM	KOD Stock Up 24% in 3 Months: Here's What You Need to Know (Zacks)
Feb-05-26 11:42AM	Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results (Zacks)
10:49AM	Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates (Zacks)
Feb-04-26 10:11AM	FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway (Zacks)
09:16AM	NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View (Zacks)
Feb-03-26 11:59AM	Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study (Zacks)
11:36AM	MRK Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '26 View (Zacks)
10:43AM	NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study (Zacks)
09:27AM	Here's Why Gilead Sciences Stock Surged 21% in a Month (Zacks)
07:52AM	Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU (Zacks)
Feb-02-26 11:03AM	Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome (Zacks)
09:40AM	Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-30-26 10:24AM	FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug (Zacks)
10:11AM	KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate (Zacks)
Jan-29-26 11:52AM	HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance (Zacks)
11:23AM	TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth (Zacks)
08:53AM	Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status (Zacks)
08:34AM	Are Options Traders Betting on a Big Move in Alkermes Stock? (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gaffin David Joseph	EVP, CLO, Alkermes, Inc.	Oct 02 '26	Sale	41.03	2,034	83,455	221,388	Oct 02 06:22 PM
Gaffin David Joseph	Officer	Oct 02 '26	Proposed Sale	41.03	2,034	83,455		Oct 02 04:04 PM
Gaffin David Joseph	EVP, CLO, Alkermes, Inc.	Sep 03 '26	Sale	48.01	2,034	97,652	223,422	Sep 03 06:32 PM
Gaffin David Joseph	Officer	Sep 03 '26	Proposed Sale	48.01	2,034	97,652		Sep 03 04:58 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Sep 01 '26	Option Exercise	24.59	5,000	122,950	74,389	Sep 01 07:08 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Sep 01 '26	Sale	46.99	9,000	422,874	65,389	Sep 01 07:08 PM
Hopkinson Craig C.	Officer	Sep 01 '26	Proposed Sale	46.99	9,000	422,874		Sep 01 04:10 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	Aug 17 '26	Sale	49.23	7,576	372,937	102,193	Aug 17 06:53 PM
Nichols Christian Todd	Officer	Aug 17 '26	Proposed Sale	49.23	7,576	372,937		Aug 17 04:50 PM
snyderman nancy lynn MD	Director	Aug 03 '26	Option Exercise	46.72	44,472	2,077,732	59,867	Aug 03 07:16 PM
snyderman nancy lynn MD	Director	Aug 03 '26	Sale	50.35	44,472	2,239,076	15,395	Aug 03 07:16 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Aug 03 '26	Option Exercise	24.48	5,000	122,404	78,389	Aug 03 07:12 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Aug 03 '26	Sale	48.58	9,000	437,220	69,389	Aug 03 07:12 PM
Gaffin David Joseph	EVP, CLO, Alkermes, Inc.	Aug 03 '26	Sale	48.58	2,034	98,812	225,456	Aug 03 07:09 PM
snyderman nancy lynn MD	Officer	Aug 03 '26	Proposed Sale	50.35	44,472	2,239,076		Aug 03 04:34 PM
Gaffin David Joseph	Officer	Aug 03 '26	Proposed Sale	48.58	2,034	98,812		Aug 03 04:32 PM
Hopkinson Craig C.	Officer	Aug 03 '26	Proposed Sale	48.58	9,000	437,220		Aug 03 04:31 PM
Gaffin David Joseph	EVP, CLO, Alkermes, Inc.	Jul 06 '26	Sale	54.03	2,034	109,897	227,490	Jul 06 04:48 PM
Gaffin David Joseph	Officer	Jul 06 '26	Proposed Sale	54.03	2,034	109,897		Jul 06 04:18 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jul 01 '26	Option Exercise	19.34	5,000	96,700	82,389	Jul 01 06:29 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jul 01 '26	Sale	51.51	9,000	463,621	73,389	Jul 01 06:29 PM
Hopkinson Craig C.	Officer	Jul 01 '26	Proposed Sale	51.51	9,000	463,621		Jul 01 04:12 PM
Wright Christopher I	Director	Jun 12 '26	Sale	45.10	2,000	90,200	25,680	Jun 12 08:04 PM
Wright Christopher I	Officer	Jun 12 '26	Proposed Sale	45.10	2,000	90,200		Jun 12 04:19 PM
Gaffin David Joseph	EVP, CLO, Alkermes, Inc.	Jun 04 '26	Sale	43.05	2,034	87,564	229,524	Jun 04 05:00 PM
Gaffin David Joseph	Officer	Jun 04 '26	Proposed Sale	43.05	2,034	87,564		Jun 04 04:16 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jun 01 '26	Option Exercise	19.34	5,000	96,700	86,389	Jun 01 07:26 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jun 01 '26	Sale	41.67	9,000	375,044	77,389	Jun 01 07:26 PM
Hopkinson Craig C.	Officer	Jun 01 '26	Proposed Sale	41.67	9,000	375,043		Jun 01 04:29 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	May 29 '26	Option Exercise	19.48	16,217	315,977	23,934	May 29 06:03 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	May 29 '26	Sale	42.36	16,217	687,007	7,717	May 29 06:03 PM
Gaffin David Joseph	EVP, CLO, Alkermes, Inc.	May 04 '26	Sale	33.20	2,034	67,529	231,558	May 04 08:42 PM
Gaffin David Joseph	Officer	May 04 '26	Proposed Sale	33.20	2,034	67,529		May 04 04:30 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	May 01 '26	Option Exercise	19.34	5,000	96,700	90,389	May 01 09:05 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	May 01 '26	Sale	33.40	9,000	300,560	81,389	May 01 09:05 PM
Hopkinson Craig C.	Officer	May 01 '26	Proposed Sale	33.40	9,000	300,560		May 01 04:22 PM
Gaffin David Joseph	EVP, CLO, Alkermes, Inc.	Apr 06 '26	Sale	34.57	2,034	70,315	233,592	Apr 06 07:56 PM
Gaffin David Joseph	Officer	Apr 06 '26	Proposed Sale	34.57	2,034	70,315		Apr 06 04:16 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Apr 01 '26	Option Exercise	19.34	5,000	96,700	94,389	Apr 01 06:58 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Apr 01 '26	Sale	35.51	9,000	319,604	85,389	Apr 01 06:58 PM
Hopkinson Craig C.	Officer	Apr 01 '26	Proposed Sale	35.51	9,000	319,604		Apr 01 04:13 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Mar 02 '26	Sale	29.29	6,890	201,808	7,717	Mar 04 08:19 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	Mar 02 '26	Sale	30.00	6,000	180,000	109,769	Mar 04 08:18 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Mar 02 '26	Option Exercise	19.34	5,000	96,700	98,389	Mar 04 08:16 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Mar 02 '26	Sale	29.72	9,000	267,485	89,389	Mar 04 08:16 PM
Gaffin David Joseph	EVP, CLO, Alkermes, Inc.	Mar 03 '26	Sale	29.76	2,034	60,532	235,626	Mar 04 08:15 PM
Gaffin David Joseph	EVP, CLO, Alkermes, Inc.	Mar 02 '26	Sale	29.29	2,034	59,576	237,660	Mar 04 08:15 PM
Gaffin David Joseph	Officer	Mar 03 '26	Proposed Sale	29.76	2,034	60,532		Mar 03 05:12 PM
Nichols Christian Todd	Officer	Mar 02 '26	Proposed Sale	30.00	6,000	180,000		Mar 02 05:15 PM
Gaffin David Joseph	Officer	Mar 02 '26	Proposed Sale	29.29	2,034	59,576		Mar 02 05:07 PM
Hopkinson Craig C.	Officer	Mar 02 '26	Proposed Sale	29.72	9,000	267,485		Mar 02 04:36 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 02 '26	Option Exercise	19.34	5,000	96,700	66,740	Feb 02 08:52 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 02 '26	Sale	33.93	9,000	305,384	57,740	Feb 02 08:52 PM
Cooke Shane	Director	Feb 02 '26	Option Exercise	31.64	61,200	1,936,368	164,944	Feb 02 08:48 PM
Cooke Shane	Director	Feb 02 '26	Sale	34.57	61,200	2,115,673	103,744	Feb 02 08:48 PM
Cooke Shane	Officer	Feb 02 '26	Proposed Sale	34.57	61,200	2,115,674		Feb 02 04:05 PM
Hopkinson Craig C.	Officer	Feb 02 '26	Proposed Sale	33.93	9,000	305,384		Feb 02 04:02 PM
Hopkinson Craig C.	Officer	Jan 08 '26	Proposed Sale	30.00	5,000	150,005		Jan 08 07:38 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 08 '26	Option Exercise	19.34	5,000	96,700	66,740	Jan 08 05:23 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 08 '26	Sale	30.00	5,000	150,005	61,740	Jan 08 05:23 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 02 '26	Sale	28.00	4,000	112,000	61,740	Jan 02 04:39 PM
Hopkinson Craig C.	Officer	Jan 02 '26	Proposed Sale	28.00	4,000	112,000		Jan 02 04:36 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 03 '25	Option Exercise	19.34	3,748	72,486	69,488	Dec 05 04:21 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 03 '25	Sale	30.00	3,748	112,447	65,740	Dec 05 04:21 PM
Hopkinson Craig C.	Officer	Dec 03 '25	Proposed Sale	30.00	3,748	112,447		Dec 03 04:32 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 01 '25	Sale	29.30	4,000	117,200	65,740	Dec 01 05:41 PM
Hopkinson Craig C.	Officer	Dec 01 '25	Proposed Sale	29.30	4,000	117,200		Dec 01 04:45 PM

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

PresidentMr. Blair C. Jackson

Senior VP & CFOMr. Joshua Reed M.B.A.

Executive VPMr. David Joseph Gaffin J.D.

Executive VP of Research & Development and Chief Medical OfficerDr. Craig C. Hopkinson M.D.

Senior VP & Chief Commercial OfficerMr. Christian Todd Nichols

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Alkermes plc

Upgrade your Finviz experience